For research use only. Not for therapeutic Use.
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research[1][2].
Alemtuzumab (Campath-IH; 0.5-5 mg/kg; ip) with a single dose results in the dose-dependent depletion of B and T lymphocytes in the peripheral blood and lymphoid organs[2].
| Catalog Number | M005249 |
| CAS Number | 216503-57-0 |
| Purity | ≥95% |
| Reference | [1]. Kashani N, et al. Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis. Front Immunol. 2021;12:706278. Published 2021 Oct 28. [2]. Yanping Hu, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009 Oct;128(2):260-70. |
